| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
72,410,000 |
| Market
Cap: |
1.55(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.37 - $21.43 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Co. has developed its Targeted Alpha Therapies, or TAT, platform together with its proprietary Fast-Clear linker technology to enable them to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Co. serves health care sectors in Canada.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
44,400 |
| Total Buy Value |
$0 |
$0 |
$0 |
$90,132 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Rawat Mohit |
President & CBO |
• – – |
2023-08-31 |
4 |
A |
$0.00 |
$0 |
D/D |
12,843 |
12,843 |
|
- |
|
| Leamon Christopher P |
Chief Scientific Officer |
• – – |
2023-08-31 |
4 |
A |
$0.00 |
$0 |
D/D |
11,957 |
11,957 |
|
- |
|
| Khuong Chau Quang |
Director |
– • – |
2022-11-11 |
4 |
A |
$2.38 |
$100,181 |
D/D |
42,093 |
42,093 |
|
- |
|
| Gannon Steven |
Director |
– • – |
2022-08-11 |
4 |
B |
$2.03 |
$90,132 |
D/D |
44,400 |
56,400 |
2.39 |
67% |
|
| Valliant John |
Chief Executive Officer |
• • – |
2022-04-27 |
4 |
AS |
$6.03 |
$27,201 |
D/D |
(4,511) |
318,147 |
|
-55% |
|
| Valliant John |
Chief Executive Officer |
• • – |
2022-04-26 |
4 |
AS |
$6.07 |
$13,032 |
D/D |
(2,147) |
322,658 |
|
-56% |
|
| Valliant John |
Chief Executive Officer |
• • – |
2022-04-25 |
4 |
AS |
$6.03 |
$12,277 |
D/D |
(2,036) |
324,805 |
|
-59% |
|
| Valliant John |
Chief Executive Officer |
• • – |
2022-04-21 |
4 |
AS |
$6.01 |
$5,541 |
D/D |
(922) |
326,841 |
|
-63% |
|
| Valliant John |
Chief Executive Officer |
• • – |
2022-04-20 |
4 |
AS |
$6.02 |
$2,209 |
D/D |
(367) |
327,763 |
|
-63% |
|
| Valliant John |
Chief Executive Officer |
• • – |
2022-04-13 |
4 |
AS |
$6.41 |
$76,882 |
D/D |
(11,994) |
328,130 |
|
-63% |
|
| Valliant John |
Chief Executive Officer |
• • – |
2022-04-12 |
4 |
AS |
$7.10 |
$129,611 |
D/D |
(18,255) |
340,124 |
|
-69% |
|
| Valliant John |
Chief Executive Officer |
• • – |
2022-04-11 |
4 |
AS |
$7.37 |
$19,162 |
D/D |
(2,600) |
358,379 |
|
-71% |
|
| Valliant John |
Chief Executive Officer |
• • – |
2022-04-08 |
4 |
AS |
$7.52 |
$6,212 |
D/D |
(826) |
360,979 |
|
-72% |
|
| Valliant John |
Chief Executive Officer |
• • – |
2022-04-07 |
4 |
AS |
$7.56 |
$9,488 |
D/D |
(1,255) |
361,805 |
|
-72% |
|
| Valliant John |
Chief Executive Officer |
• • – |
2022-04-06 |
4 |
AS |
$7.58 |
$758 |
D/D |
(100) |
363,060 |
|
-73% |
|
| Valliant John |
Chief Executive Officer |
• • – |
2022-04-05 |
4 |
AS |
$7.67 |
$16,107 |
D/D |
(2,100) |
363,160 |
|
-73% |
|
| Valliant John |
Chief Executive Officer |
• • – |
2022-04-04 |
4 |
AS |
$7.81 |
$5,467 |
D/D |
(700) |
365,260 |
|
-72% |
|
| Valliant John |
Chief Executive Officer |
• • – |
2022-04-01 |
4 |
AS |
$7.75 |
$7,750 |
D/D |
(1,000) |
365,960 |
|
-75% |
|
| Valliant John |
Chief Executive Officer |
• • – |
2022-03-30 |
4 |
AS |
$7.52 |
$2,256 |
D/D |
(300) |
366,960 |
|
-74% |
|
| Valliant John |
Chief Executive Officer |
• • – |
2022-03-29 |
4 |
AS |
$7.52 |
$1,504 |
D/D |
(200) |
367,260 |
|
-71% |
|
| Valliant John |
Chief Executive Officer |
• • – |
2022-03-28 |
4 |
AS |
$7.55 |
$72,480 |
D/D |
(9,600) |
367,460 |
|
-71% |
|
| Valliant John |
Chief Executive Officer |
• • – |
2022-03-25 |
4 |
AS |
$7.42 |
$3,710 |
D/D |
(500) |
377,060 |
|
-70% |
|
| Valliant John |
Chief Executive Officer |
• • – |
2022-03-23 |
4 |
AS |
$7.50 |
$750 |
D/D |
(100) |
378,260 |
|
-70% |
|
| Valliant John |
Chief Executive Officer |
• • – |
2022-03-22 |
4 |
AS |
$7.53 |
$30,120 |
D/D |
(4,000) |
378,360 |
|
-69% |
|
| Valliant John |
Chief Executive Officer |
• • – |
2022-03-21 |
4 |
AS |
$7.46 |
$5,222 |
D/D |
(700) |
377,560 |
|
-69% |
|
76 Records found
|
|
Page 1 of 4 |
|
|
0.02 (0.09%) 
